Pravin T Kaumaya, PhD

College

College of Medicine

Department/Division

Obstetrics & Gynecology

Academic Title

Professor

Research Program

Translational Therapeutics

Research Interest

Cancer ● Mammary Cancer, Experimental ● Breast Cancer ● Encephalomyelitis, Autoimmune, Experimental ● Lung Cancer ● Disease Models, Animal ● Neovascularization, Pathologic ● Cancer, Experimental ● Infection ● HTLV-I Infections

As a member of the Translational Therapeutics Program at the OSUCCC – James, Pravin Kaumaya, PhD, focuses his research on directing patient immune systems to recognize and kill their own cancer cells.

One of his recent studies of potential therapeutic agents for brain tumors reformatted the toxicity profile of cisplatin-diamminedichloroplatinum (cis-DDP) and demonstrated therapeutic efficacy of PEP455-Pt bioconjugate in F98 glioma-bearing rats.

Dr. Kaumaya has co-authored many articles in well-known publications, including the Journal of Immunology, Immunotherapy and Discovery Medicine.

Office Location

316 Tzagournis Med Res Facility

420 W 12th Ave, Columbus, OH 43210

614-292-7028

614-292-1135

kaumaya.1@osu.edu;PRAVIN.KAUMAYA@OSUMC.EDU

Publications

Phase 1 Immunotherapy Trial with Two Chimeric HER-2 B-Cell Peptide Vaccines emulsified in Montanide ISA 720VG and nor-MDP Adjuvant in Advanced Solid Tumors.

Bekaii-Saab T, Wesolowski R, Ahn DH, Wu C, Mortazavi A, Lustberg MB, Ramaswamy B, Fowler J, Wei L, Overholser J, Kaumaya PTP

Clin Cancer Res in press 02/25/2019
Phase 1 Immunotherapy Trial with Two Chimeric HER-2 B-Cell Peptide Vaccines emulsified in Montanide ISA 720VG and nor-MDP Adjuvant in Advanced Solid Tumors.

Bekaii-Saab T, Wesolowski R, Ahn DH, Wu C, Mortazavi A, Lustberg MB, Ramaswamy B, Fowler J, Wei L, Overholser J, Kaumaya PTP

Clin Cancer Res in press 02/25/2019
Design, synthesis, and evaluation of cisplatin-containing EGFR targeting bioconjugates as potential therapeutic agents for brain tumors.

Barth RF, Wu G, Meisen WH, Nakkula RJ, Yang W, Huo T, Kellough DA, Kaumaya P, Turro C, Agius LM, Kaur B

Onco Targets Ther 9 2769-81 01/01/2016
Anti-Tumor Effects of Peptide Therapeutic and Peptide Vaccine Antibody Co-targeting HER-1 and HER-2 in Esophageal Cancer (EC) and HER-1 and IGF-1R in Triple-Negative Breast Cancer (TNBC).

Overholser J, Ambegaokar KH, Eze SM, Sanabria-Figueroa E, Nahta R, Bekaii-Saab T, Kaumaya PT

Vaccines (Basel) 3 519-43 07/06/2015
A paradigm shift: Cancer therapy with peptide-based B-cell epitopes and peptide immunotherapeutics targeting multiple solid tumor types: Emerging concepts and validation of combination immunotherapy.

Kaumaya PT

Hum Vaccin Immunother 11 1368-86 01/01/2015

See Full List

Back to Researcher Search

Find a Researcher
Find a Clinical Trial

Please enter a keyword (i.e. Name, Research Interest) or choose a Research Program

By Name or Keyword

OR

By Research Program

Please enter a keyword (i.e. Name, Cancer Type) or choose a Principle Investigator

Pravin T Kaumaya, PhD

College

Department/Division

Academic Title

Research Program

Research Interest

Office Location

Publications

Phase 1 Immunotherapy Trial with Two Chimeric HER-2 B-Cell Peptide Vaccines emulsified in Montanide ISA 720VG and nor-MDP Adjuvant in Advanced Solid Tumors.

Phase 1 Immunotherapy Trial with Two Chimeric HER-2 B-Cell Peptide Vaccines emulsified in Montanide ISA 720VG and nor-MDP Adjuvant in Advanced Solid Tumors.

Design, synthesis, and evaluation of cisplatin-containing EGFR targeting bioconjugates as potential therapeutic agents for brain tumors.

Anti-Tumor Effects of Peptide Therapeutic and Peptide Vaccine Antibody Co-targeting HER-1 and HER-2 in Esophageal Cancer (EC) and HER-1 and IGF-1R in Triple-Negative Breast Cancer (TNBC).

A paradigm shift: Cancer therapy with peptide-based B-cell epitopes and peptide immunotherapeutics targeting multiple solid tumor types: Emerging concepts and validation of combination immunotherapy.

OR

OR

Search for Clinical Trials

Find a Scientific Publication

Pravin T Kaumaya, PhD

College

Department/Division

Academic Title

Research Program

Research Interest

Office Location

Publications

Phase 1 Immunotherapy Trial with Two Chimeric HER-2 B-Cell Peptide Vaccines emulsified in Montanide ISA 720VG and nor-MDP Adjuvant in Advanced Solid Tumors.

Phase 1 Immunotherapy Trial with Two Chimeric HER-2 B-Cell Peptide Vaccines emulsified in Montanide ISA 720VG and nor-MDP Adjuvant in Advanced Solid Tumors.

Design, synthesis, and evaluation of cisplatin-containing EGFR targeting bioconjugates as potential therapeutic agents for brain tumors.

Anti-Tumor Effects of Peptide Therapeutic and Peptide Vaccine Antibody Co-targeting HER-1 and HER-2 in Esophageal Cancer (EC) and HER-1 and IGF-1R in Triple-Negative Breast Cancer (TNBC).

A paradigm shift: Cancer therapy with peptide-based B-cell epitopes and peptide immunotherapeutics targeting multiple solid tumor types: Emerging concepts and validation of combination immunotherapy.

Related Links

OR

OR

Search for Clinical Trials

Find a Scientific Publication